High CTNND1, EMP1, or IFITM3 expression predicts poor event-free survival. (A) Event-free survival analysis of US cohort (left) and DCOG/COALL cohort (right) B-ALL patients separated by IKZF1 mutation status as indicated. Log-rank p-values are shown. (B–D) EFS analysis as described for A, but separating cohorts based on median expression of (B) CTNND1, (C) EMP1, and (D) IFITM3. Expression of each gene across samples (determined by RNA-seq for US cohort and microarray for DCOG/COALL cohort with probeset indicated) are shown in Figs. S3 and S4. (E and F) EFS for DCOG/COALL patients grouped by IKZF1 deletion status (E) or BCR-ABL1⁺/like subgroup status (F), and then further separated based on median expression of CTNND1. (G and H) EFS for DCOG/COALL patients grouped by IKZF1 deletion status, and then further separated based on median expression of EMP1 (G) or IFITM3 (H).